References
- Bretzel RG, Arnolds S, Medding J, et al. A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care 2004;27:1023-27
- Anderson JH Jr, Brunelle RL, Keohane P, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycaemia in patients with non-insulin dependent diabetes mellitus. Arch Intern Med 1997;157:1249-55
- Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin Ther 1997;19:62-72
- Dailey G, Rosenstock J, Moses RG, et al. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004;27:2363-8
- Home PD, Lindholm A, Riis A; European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000;17:762-71
- Raskin P, Guthrie RA, Leiter L, et al. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000;23:583-8
- Brunner GA, Hirschberger S, Sendlhofer G, et al. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabet Med 2000;17:371-5
- Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res 2008;6:54-67
- Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart – a randomized double-blind cross-over trial in type 1 diabetes mellitus. Diabetes Care 1999;22:801-5
- Heinemann L, Kapitza C, Starke AA, et al. Time-action profile of the insulin analogue B28Asp. Diabet Med 1996;13:683-7
- Leichter S. Is the use of insulin analogues cost-effective? Adv Ther 2008;25:285-99
- Hall JA, Summers KH, Obenchain RL, et al. Cost and utilization comparisons between propensity score-matched insulin lispro and regular insulin users. J Manag Care Pharm 2003;9:263-8
- Chen K, Chang EY, Summers KH, et al. Comparison of costs and utilization between users of insulin lispro versus users of regular insulin in a managed care setting. J Manag Care Pharm 2005;11:376-82
- Aagren M, Luo W, Moës E, et al. Healthcare utilization changes in relation to treatment intensification with insulin aspart in patients with type 2 diabetes. J Med Econ 2010;13:16-22
- llano MF, Al-Zakwani IS, Fisher MD, et al. Differences in hypoglycaemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin 2005;21:291-8
- Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712-25
- Gundgaard J, Christensen TE, Thomsen TL. Direct healthcare costs of patients with type 2 diabetes using long-acting insulin analogues or NPH insulin in a basal insulin-only regimen. Prim Care Diabetes 2010, May 7. [Epub ahead of print]
- Statistics Denmark. www.dst.dk, last accessed 3 August 2010
- The Danish Register of Medicinal Product Statistics. http://www.dkma.dk/1024/visUKLSArtikel.asp?artikelID=10895, last accessed 3 August 2010
- National Registry of Patients. http://www.sst.dk/Indberetning%20og%20statistik/Landspatientregisteret.aspx, last accessed 3 August 2010
- National Health Insurance Registry. http://www.sst.dk/Indberetning%20og%20statistik/Sundhedsstyrelsens%20registre/Sygesikringsregister.aspx, last accessed 3 August 2010
- Dehijia RH, Wahba S. Propensity score-matching methods for nonexperimental causal studies. Rev Econ Stat 2002;84:151-61
- Foster EM. Propensity score matching: an illustrative analysis of dose response. Med Care 2003;41:1183-92
- Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999;150:327-33
- Månsson R, Joffe MM, Sun W, et al. On the estimation and use of propensity scores in case-control and case-cohort studies. Am J Epidemiol 2007;166:332-9
- Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40
- Atkinson SE, Wilson PW. Comparing mean efficiency and productivity scores from small samples: a bootstrap methodology. J Prod Anal 1995;6:137-52
- Efron B. Nonparametric estimates of standard error: The jackknife, the bootstrap and other methods. Biometrika 1981;68:589-99
- www.medstat.dk, last accessed 16 June 2010